Science, Research & Innovation
Why do 90 percent of disease‑driving proteins remain out of reach for today’s medicines?
In this conversation, Bayer CEO Bill Anderson sits down with Aleksandra Rizo, CEO of Vividion Therapeutics, our arm's length company, to explore this and other questions like:
What makes small molecules so powerful for access and convenience, and how is Vividion flipping the script on proteins once considered “undruggable”?
What’s happening in research and the early clinical trials for patients facing squamous non‑small cell lung cancer and colorectal cancer, and could a new medicine reach patients by the end of this decade?
In this episode, Bayer CEO Bill Anderson dives into the world of maize farming in Zambia to explore how we are reimagining modern seed technology.
In this episode, we tackle menopause and the critical need for hormone-free treatments for hot flashes. Our CEO, Bill Anderson chats with external communications director Nicole Hayes, and Yesmean Wahdan, the U.S. VP of Medical Affairs, to dive into the innovative approaches our team is taking to develop effective solutions that empower women to reclaim their comfort and confidence.
In this episode of "Science Is Boss," Bayer CEO Bill Anderson talks to Michael Schmidt, a former pharmacist, about how his team transformed Iberogast, a trusted liquid digestive health product for sixty years, into a new convenient soft gel format for U.S. consumers.
In the third episode of "Science Is Boss," Bayer CEO Bill Anderson talks to Jamie Chow, a former radiologist, about how AI is transforming patient care in radiology.
In the second episode of "Science Is Boss," Bayer CEO Bill Anderson talks to Brianna White in Bayer's Crop Science division about how her team is making corn shorter and more resistant to extreme weather.
In this episode, Bayer CEO Bill Anderson and Ruth Shah, a trained cell and molecular biologist, delve into the potential of cell and gene therapies to fundamentally change the way we treat diseases like Parkinson's.